WO2001087335A2 - Procede d'inhibition selective de la ghreline - Google Patents

Procede d'inhibition selective de la ghreline Download PDF

Info

Publication number
WO2001087335A2
WO2001087335A2 PCT/US2001/011752 US0111752W WO0187335A2 WO 2001087335 A2 WO2001087335 A2 WO 2001087335A2 US 0111752 W US0111752 W US 0111752W WO 0187335 A2 WO0187335 A2 WO 0187335A2
Authority
WO
WIPO (PCT)
Prior art keywords
ghrelin
ghs
compound
gna
mixture
Prior art date
Application number
PCT/US2001/011752
Other languages
English (en)
Other versions
WO2001087335A3 (fr
Inventor
Henry Uhlman Bryant
Mark Louis Heiman
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Priority to AU2001259056A priority Critical patent/AU2001259056A1/en
Priority to EP01932539A priority patent/EP1286697A2/fr
Priority to US10/258,259 priority patent/US20030211967A1/en
Publication of WO2001087335A2 publication Critical patent/WO2001087335A2/fr
Publication of WO2001087335A3 publication Critical patent/WO2001087335A3/fr
Priority to US11/106,899 priority patent/US20050201938A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Definitions

  • the present invention is in the field of human medicine, particularly in the treatment of obesity and disorders associated with obesity such as diabetes mellitus. More specifically the invention relates to a method for treating obesity by administering a compound which blocks ghrelin action.
  • the present invention provides a method of selectively inhibiting ghrelin activity in a mammal comprising administering to a mammal in need thereof a therapeutically-effective amount of a compound selected from the group consisting of a growth hormone secretagogue receptor antagonist (GHS-RA) and a ghrelin neutralizing agent (GNA) .
  • the invention further provides a method for treating obesity and related disorders in a mammal comprising administering to a mammal in need thereof a therapeutically-effective amount of a compound selected from the group consisting of a growth hormone secretagogue receptor antagonist (GHS-RA) and a ghrelin neutralizing agent (GNA) .
  • Other embodiments include in vi tro and in vivo screening and assay methods .
  • GHRH growth hormone-releasing peptides
  • GHS-R GHS receptor
  • Obesity also called diverence or fatness
  • body fat usually caused by the consumption of more calories than the body uses. The excess calories are then stored as fat, or adipose tissue.
  • Overweight if moderate, is not necessarily obesity, particularly in muscular or large-boned individuals . In general, however, a body weight 20 percent or more over the optimum tends to be associated with obesity.
  • treating or treatment describes the management and care of a patient for the purpose of combating the disease, condition, or disorder.
  • Treating includes the administration of a compound of present invention to prevent the onset of the symptoms or complications, alleviating the symptoms or complications, or eliminating the disease, condition, or disorder.
  • Treating obesity therefore includes the inhibition of food intake, the inhibition of weight gain, and inducing weight loss in patients in need thereof.
  • the term 'related disorders' includes but is not limited to type II diabetes, cardiovascular disease, cancer, and other disease states whose etiology stems from obesity.
  • the term 'administering' or 'administration' as used herein includes any means for introducing a GHS-RA or GNA into the body such that the substance is able to interact with the GHS-R or secreted ghrelin.
  • Preferred routes of administration will introduce the substance into the systemic circulation. Examples include but are not limited to oral; transdermal; subcutaneous, intravenous, and intramuscular injection.
  • the active agents of the present invention are administered to a mammal, preferably a human, in accord with known methods, such as intravenous administration as a bolus or by continuous infusion over a period of time, by intramuscular, intraperitoneal, intracerebral, intracerobrospinal, subcutaneous, intra-articular, intrasynovial, intrathecal, intraocular, intralesional, oral, topical, inhalation or through sustained release.
  • a therapeutically-effective amount is at least the minimal dose, but less than a toxic dose, of an active agent which is necessary to impart therapeutic benefit to a mammal. Stated another way, a therapeutically-effective amount is an amount which induces, ameliorates or otherwise causes an improvement in the obese state of the mammal.
  • Carriers' as used herein include pharmaceutically- acceptable carriers, excipients, or stabilizers which are nontoxic to the cell or mammal being exposed thereto at the dosages and concentrations employed. Often the physiologically-acceptable carrier is an aqueous pH buffered solution.
  • physiologically acceptable carriers include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid; low molecule weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt- forming counterions such as sodium; and/or nonionic surfactants such as TWEEN®, polyethylene glycol (PEG) , and PLURONICS®.
  • buffers such as phosphate, citrate, and other organic acids
  • antioxidants including ascorbic acid
  • low molecule weight (less than about 10 residues) polypeptides proteins, such as serum
  • 'mammal' refers to any animal classified as a mammal, including humans, domestic, farm and zoo animals, and sports or companion animals, etc. In a preferred embodiment of the invention, the mammal is a human.
  • 'antibody' is used in the broadest sense and specifically includes monoclonal antibodies, chimeric antibodies, humanized antibodies, and fully human antibodies .
  • 'monoclonal antibody' refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally-occurring mutations that may be present in minor amounts .
  • Antibody fragments means a portion of an intact antibody, preferably the antigen binding or variable region of the intact antibody.
  • antibody fragments include Fab, Fab', F(ab')l and Fv fragments; diabodies; linear antibodies (Zapata et al . , Protein Engin . S(10): 1057-1 062 (1991)); single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.
  • the term 'Fv' is the minimum antibody fragment, which contains a complete antigen-recognition and binding site. This region consists of a dimer of one heavy- and one light chain variable domain in tight, non-covalent association.
  • variable domain the three complementarity-determining regions (CDRs) of each variable domain interact to define an antigen-binding site on the surface of the VH-VL dimer.
  • CDRs complementarity-determining regions
  • the Fab fragment also contains the constant domain of the light chain and the 'first constant domain (CHI) of the heavy chain.
  • Fab fragments differ from Fv fragments by the addition of a few residues at the carboxy terminus of the heavy chain CHI domain including one or more cysteines from the antibody hinge region.
  • Fab'-SH is the designation herein for Fab' in which the cysteine residue (s) of the constant domains bear a free thiol group.
  • F(ab') z antibody fragments originally were produced as pairs of Fab' fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.
  • Papain digestion of antibodies produces two identical antigen-binding fragments, called Fab fragments, each with a single antigen-binding site, and a residual Fc fragment, a designation reflecting the ability to crystallize readily.
  • Pepsin treatment yields an F(ab') 2 fragment that has two antigen-combining sites and is still capable of cross- linking antigen.
  • immunoglobulins The 'light chains' of antibodies (immunoglobulins) from any vertebrate species can be assigned to one of two clearly distinct types, called kappa and lambda, based on the amino acid sequences of their constant domains .
  • immunoglobulins can be assigned to different classes. There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes) , e.g., IgGl, IgG2, IgG3, IgG4, IgA and IgA2.
  • Fv'Single-chain Fv' antibody fragments comprise the VH and VL domains of antibody, wherein these domains are present in a single polypeptide chain.
  • the Fv polypeptide further comprises a polypeptide linker between the VH and VL domain, which enables the sFv to form the desired structure for antigen binding.
  • the term ' immunoadhesion' designates antibodylike molecules that combine the binding specificity of a heterologous protein (an 'adhesion') with the effector functions of immunoglobulin constant domains.
  • the immunoadhesions comprise a fusion of an amino acid sequence with the desired binding specificity which is other than the antigen recognition and binding site of an antibody (i.e., is heterologous), and an immunoglobulin constant domain sequence.
  • the adhesion part of an immunoadhesion molecule typically is a contiguous amino acid sequence comprising at least the binding site of a receptor or a ligand.
  • the immunoglobulin constant domain sequence in the immunoadhesion may be obtained from any immunoglobulin, such as IgG-1, IgG-2, IgG-3 or IgG-4 subtypes, IgA (including IgG-1 and IgA-2) , IgE, IgD or IgM.
  • 'diabodies' refers to small antibody fragments with two antigen-binding sites, which fragments comprise a heavy-chain variable domain (VH) connected to a light chain variable domain (VL) in the same polypeptide chain (VH-VL) .
  • VH heavy-chain variable domain
  • VL light chain variable domain
  • Diabodies are described more fully in, for example, EP 404.097, WO 93/1 1161; and Hollinger et al . , Proc. Natl. Acad. Sci . USA 90: 6444-6448 (1993) .
  • a GHS-RA is any compound that partially or fully antagonizes, blocks, or otherwise inhibits the biological action of ghrelin by binding to the GHS-R without stimulating the release of growth hormone. Therefore GHS (compounds that bind the GHS-R and stimulate the release of GH) are not consistent with the claimed method.
  • GHS-RA are compounds useful in the presently claimed method and include but are not limited to natural products, synthetic organic compounds, peptides, proteins, antibodies, antibody fragments, single chain antibodies, and antibody based constructs. The current level of skill in the art of receptor binding and growth hormone assays places GHS-RAs well within the grasp of the ordinarily skilled artisan. There are several routine approaches for identifying a GHS-R.
  • GHS-RA test compound is first checked to determine if it binds GHS-R. This is accomplished using routine radiometric binding methods .
  • a second messenger reporter such as calcium can be used to determine binding.
  • Assay is described in Kojima et al . , Nature 402: 656-60 (1999). Compounds that bind GHS-R are then exposed to primary pituitary cells, for example, and release of growth hormone is determined using standard commercially available assays.
  • Compounds that bind but do not stimulate the release of GH should then be assayed for ghrelin antagonism by exposing pituitary cells to the GHS-RA in the presence of ghrelin and then assaying for GH release.
  • Antibody-based GHS-RAs are also consistent with the claimed method.
  • Anti-GHS-R antibodies may be generated by a variety of well-known methods that include traditional antisera production and monoclonal antibody techniques.
  • Ghrelin neutralizing agents represent another aspect of the invention.
  • ghrelin is neutralized or otherwise rendered biologically inactive apart from the receptor.
  • Agents suitable for this application are those which specifically bind ghrelin, preferably with a higher affinity constant than the GHS-R.
  • Antibody or antibody-based agents are preferred because they can be purposefully generated using well established techniques.
  • Kojima et al . Nature 402: 656-60 (1999) .
  • Immunoadhesions Fc fusion constructs, similar to Enbrel®, where the soluble ligand-binding domain of the GHS- R is fused to a human Fc
  • Dosages and desired drug concentration of pharmaceutical compositions of the present invention may vary depending on the particular use envisioned. The determination of the appropriate dosage or route of administration is well within the skill of an ordinary artisan. Animal experiments provide reliable guidance for the determination of effective doses for human therapy.
  • an article of manufacture containing materials useful in the presently claimed methods comprises a container and a label.
  • Suitable containers include, for example, bottles, vials, syringes, and test tubes .
  • the containers may be formed from a variety of materials such as glass or plastic.
  • the container holds a composition which is effective for specifically inhibiting ghrelin action and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle) .
  • the active agent in the composition is a GHS-RA and/or a GNA.
  • the label on, or associated with, the container indicates that the composition is used for treating obesity and/or related disorders.
  • the article of manufacture may further comprise a second container comprising a pharmaceutically-acceptable buffer, such as phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial end user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for use.
  • Five-minute fractions were collected while monitoring the U.V. at 214 nm (2.0A).
  • the appropriate fractions were combined, frozen and lyophilized.
  • MALDI- ass spectral analysis indicated a mass of 3313.85 g for the purified ghrelin, which was consistent with the theoretical molecular weight.
  • Example 2 Animals Wild-type mice (129SV strain) and NPY-knockout mice were obtained from Taconic Farms ® . Eight-week old dwarf rats were purchased at Harlan UK. Animals were housed individually in a temperature controlled environment (25 C°) with a 12-hour light and 12-hour dark (18.00 - 06.00) photoperiod. All mice had ad libi tum access to pelleted mouse food (5008 PMI ® Nutrition International) and tap water . Mice were between 9 and 13 weeks of age and were injected daily between 17.00 and 18.00 with 0.1 ml of phosphate buffered saline (PBS) containing 0 or 8 mg/kg/d ghrelin over 13 days . Food intake and body weights were measured daily at O ⁇ .OOh. All animal experiments were conducted in accordance with the principles and procedures outlined in the National Institute of Health (NIH) Guide for the Care and Use of Laboratory Animals.
  • NASH National Institute of Health
  • RQ is the ratio of VC0 2 to V0 2 .
  • CV calorific value of oxygen
  • Total calories expended were calculated to determine daily fuel utilization.
  • proportion of protein, fat and carbohydrate that is utilized during that 24-hour period we used Flatt's proposal and assumed that protein utilization was equivalent to protein intake for adult stable animals (Flatt, J.P., J. Nutr Biochem 2, 193-202 (1991)).
  • DXA dual-energy X-ray absorptiometry
  • Body composition was measured on day 14 of the treatment period by DXA using a Norland p-DEXA ® (Norland,
  • the system provides a non-invasive method for quantification of whole body composition and is based on the differential attenuation of high and low energy x-rays by the tissues in the scan area.
  • Soft tissues attenuate the energy beam less than bone; of the soft tissue mass, fat tissue attenuates the beam less than lean tissue.
  • Fat mass consists primarily of adipose tissue, but lean mass includes organs, tendons, cartilage, blood and body water in addition to skeletal muscle. In the present study, fat mass, lean mass and bone mineral content (bone mass) were measured and reported. Mice were anesthetized with inhalation of isoflorane and placed on the instrument platform in ventral position. Measurements were performed at a speed of 10 mm/ in and a resolution of 0.5 x 0.5 mm. Quality controls using phantom ID2232 and Calibration Standard 82315 (Norland) were performed before starting measurements .
  • Example 5 Example 5
  • mice were treated with GHRP-2 for 18 days.
  • Hypothalamic RNA levels (measured by RT-PCR) of neuropeptide Y (NPY) , agouti-related-protein (AGRP) , pro- opio-melanocortin (POMC) and melanocyte-concentrating hormone (MCH) were not changed.
  • GHRP-6 increases c- fos expression in NPY-neurons (Vernon, R. G.; J Endocrinol 150, 129-40 (1996)) and because these neurons also release AGRP, a natural melanocyte stimulating hormone antagonist
  • Recombinant CHO cells expressing the human growth hormone secretagogue receptor cDNA described by Howard et al . , Science 273: 974-977 (1996) are grown and harvested in nutrient medium.
  • Membrane preparations are then obtained by first washing the cells with PBS buffer, then twice washing with cold buffer (25 mM HEPES, 2 M MgCl 2 , 1 mM EDTA, 20 ⁇ g/ml Leupeptin, 1 mM PMSF, 2 ⁇ g/ml Aprotinin, 50 ⁇ g/ml Trypsin Inhibitor, pH 8.0) and resuspending in buffer.
  • the cell suspension is lysed in a glass Teflon® homogenizer, and the resulting sample is then centrifuged at 35,300 X g for 30 minutes at 4°C.
  • the supernatant is removed, and the pellet is resuspended in cold buffer and homogenized. Aliquots may then be prepared and stored at -80°C.
  • a sample of the membrane preparation is pre- incubated with a test compound or a control compound with and without added grhelin in buffer (25 mM HEPES, 0.2%
  • BSA 2.6 mM Mg, 0.8 mM ATP, 0.1 mM GTP, 5 mM creatine phosphate, creatine kinase 50 U/ml, 0.2 mM IBMX, pH 7.6) is added and incubated for an additional 30 minutes. Incubations are stopped by adding 10 mM EDTA.
  • cAMP-b phycoerythrin conjugate is added followed by the addition of affinity purified anti-cAMP rabbit antiserum.
  • anti-rabbit IgG coated assay beads are added and incubated for an additional 15 minutes. Plates are then evacuated and read on a Pandex® PFCIA reader.
  • ghrelin binding shows decreasing fluorescent intensity due to increased cAMP concentration. Fluorescent intensity values are correlated to rate of cAMP production (pmol/min/mg) . Conversely, inhibition of ghrelin binding by either receptor blockade or ghrelin neutralizations shows no decrease in fluorescent intensity.
  • ghrelin is mainly generated by the stomach and secreted into circulation
  • total energy 1795 ⁇ 105 kcal
  • plasma ghrelin decreased by 30% 2 hours after the meal (p ⁇ 0.01), and over the 24h sampling period (p ⁇ 0.05).
  • plasma ghrelin levels did not decrease after meals.
  • ghrelin release is a normal response to fasting.
  • Such elevated ghrelin stimulates appetite and the utilization of carbohydrate (determined in above examples using rodents) and thus corrects hypoglycemia resulting from fasting.
  • Ingestion of glucose rescues hypogylcemia and thus inhibits ghrelin secretion from the stomach to prevent hyperglycemia .
  • ghrelin plays an important role in the regulation of blood glucose. Agents that block ghrelin action may be useful for the treatment of diabetes .

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)

Abstract

L'invention concerne un procédé d'inhibition sélective de la ghreline permettant de traiter une série de maladies, y compris l'obésité et les troubles connexes, en particulier chez les individus qui ont des prédispositions génétiques. Selon un aspect, le procédé consiste à administrer un agent qui neutralise efficacement la ghreline, et selon un autre aspect ce procédé consiste à administrer un antagoniste de récepteur de ghreline (récepteur sécrétagogue d'hormone de croissance).
PCT/US2001/011752 2000-05-17 2001-05-07 Procede d'inhibition selective de la ghreline WO2001087335A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2001259056A AU2001259056A1 (en) 2000-05-17 2001-05-07 Method for selectively inhibiting ghrelin action
EP01932539A EP1286697A2 (fr) 2000-05-17 2001-05-07 Procede d'inhibition selective de la ghreline
US10/258,259 US20030211967A1 (en) 2001-05-07 2001-05-07 Method for selectively inhibiting ghrelin action
US11/106,899 US20050201938A1 (en) 2000-05-17 2005-04-15 Method for selectively inhibiting ghrelin action

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20489700P 2000-05-17 2000-05-17
US60/204,897 2000-05-17

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/106,899 Continuation US20050201938A1 (en) 2000-05-17 2005-04-15 Method for selectively inhibiting ghrelin action

Publications (2)

Publication Number Publication Date
WO2001087335A2 true WO2001087335A2 (fr) 2001-11-22
WO2001087335A3 WO2001087335A3 (fr) 2002-05-16

Family

ID=22759933

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/011752 WO2001087335A2 (fr) 2000-05-17 2001-05-07 Procede d'inhibition selective de la ghreline

Country Status (3)

Country Link
EP (1) EP1286697A2 (fr)
AU (1) AU2001259056A1 (fr)
WO (1) WO2001087335A2 (fr)

Cited By (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002060472A1 (fr) * 2001-01-31 2002-08-08 Chugai Seiyaku Kabushiki Kaisha Remedes pour des etats d'hyponutrition
WO2002090387A1 (fr) * 2001-05-10 2002-11-14 Queensland University Of Technology Diagnostic et therapie des cancers du systeme reproducteur
WO2003051389A3 (fr) * 2001-12-18 2003-09-12 Theratechnologies Inc Compositions pharmaceutiques comprenant de la ghreline non acylee et utilisations therapeutiques de ces compositions
WO2004002986A2 (fr) 2002-06-28 2004-01-08 Banyu Pharmaceutical Co., Ltd. Nouveaux dérivés de benzimidazole
WO2004004772A1 (fr) * 2002-07-05 2004-01-15 Chugai Seiyaku Kabushiki Kaisha Traitement antidiabetique
WO2004013274A2 (fr) 2002-08-01 2004-02-12 Noxxon Pharma Ag Acides nucleiques a liaison de ghreline
WO2004024183A1 (fr) * 2002-09-12 2004-03-25 Pharmexa A/S Immunisation contre la ghreline autologue
US6716629B2 (en) 2000-10-10 2004-04-06 Biotrove, Inc. Apparatus for assay, synthesis and storage, and methods of manufacture, use, and manipulation thereof
WO2004056869A1 (fr) * 2002-12-20 2004-07-08 7Tm Pharma A/S Agoniste inverse du recepteur de la ghreline pour reguler des comportements alimentaires
WO2004084943A1 (fr) * 2003-03-19 2004-10-07 Beth Israel Deaconess Medical Center, Inc Utilisation d'antagonistes de la ghrelin ou du recepteur de la ghrelin pour traiter l'inflammation intestinale
WO2005000343A1 (fr) * 2003-06-11 2005-01-06 Allergan, Inc. Utilisation d'une toxine clostridiale pour reduire l'appetit
WO2005026211A2 (fr) * 2003-09-05 2005-03-24 Eli Lilly And Company Anticorps anti-ghreline
EP1546389A2 (fr) * 2002-09-06 2005-06-29 Elixir Pharmaceuticals, Inc. Regulation de l'axe hormone de croissance/igf-1
WO2005097830A2 (fr) * 2004-04-07 2005-10-20 Aditech Pharma Ab Utilisations d'elements de liaison isoles capables de reduire l'activite biologique de composes secretagogues
WO2005097831A2 (fr) * 2004-04-07 2005-10-20 Gastrotech Pharma A/S Utilisations d'elements de liaison isoles capables de se lier specifiquement a des secretagogues
WO2005113600A2 (fr) * 2004-05-18 2005-12-01 Haptogen Ltd Methodes de regulation, de traitement et de prise en charge de l'obesite
WO2005112903A2 (fr) * 2004-05-14 2005-12-01 Novo Nordisk A/S Utilisation d'antagonistes de la ghrelin pour le traitement de certaines maladies du systeme nerveux central
WO2006019577A1 (fr) * 2004-07-14 2006-02-23 Eli Lilly And Company Anticorps anti-ghreline
EP1694355A1 (fr) * 2003-10-24 2006-08-30 THE ACADEMIC HOSPITAL ROTTERDAM acting under the name Erasmus MC Utilisation de compositions de ghreline et de ghreline non acylee dans des etats pathologiques lies a l'insuline
WO2006091381A1 (fr) * 2005-02-23 2006-08-31 Eli Lilly And Company Anticorps anti-ghreline humanises
WO2007041052A2 (fr) 2005-09-29 2007-04-12 Merck & Co., Inc. Derives spiropiperidines acyles convenant comme modulateurs des recepteurs de la melanocortine-4
JP2007513608A (ja) * 2003-11-10 2007-05-31 ノクソン・フアルマ・アクチエンゲゼルシヤフト 生物活性グレリンに特異的に結合する核酸
US7252665B2 (en) 2003-10-31 2007-08-07 Medtronic, Inc Ablation of stomach lining to reduce stomach acid secretion
WO2007095347A2 (fr) * 2006-02-13 2007-08-23 The Gov. Of The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Procedes et compositions associes aux antagonistes du ghs-r
US7282050B2 (en) 2003-10-31 2007-10-16 Medtronic, Inc. Ablation of exterior of stomach to treat obesity
WO2008060476A2 (fr) 2006-11-15 2008-05-22 Schering Corporation Composés hétérocycliques contenant de l'azote et leurs procédés d'utilisation
EP2088154A1 (fr) 2004-03-09 2009-08-12 Ironwood Pharmaceuticals, Inc. Procédés et compositions pour le traitement de troubles gastro-intestinaux
WO2009110510A1 (fr) 2008-03-06 2009-09-11 萬有製薬株式会社 Dérivé d'alkylaminopyridine
EP2127676A2 (fr) 2004-11-01 2009-12-02 Amylin Pharmaceuticals, Inc. Traitement de l'obésité et les maladies et troubles liés à l'obésité
US7666833B2 (en) 2001-12-18 2010-02-23 Alizé Pharma SAS Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
WO2010047982A1 (fr) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Nouveaux dérivés de benzimidazole cycliques utiles comme agents anti-diabétiques
WO2010051236A1 (fr) 2008-10-30 2010-05-06 Merck Sharp & Dohme Corp. Antagonistes d'isonicotinamide des récepteurs de l'orexine
WO2010051206A1 (fr) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Nouveaux agents antidiabétiques utiles avec des dérivés de benzimidazole cycliques
US7736392B2 (en) 2005-04-28 2010-06-15 Medtronic, Inc. Bulking of upper esophageal sphincter for treatment of obesity
WO2010075068A1 (fr) 2008-12-16 2010-07-01 Schering Corporation Dérivés de pyridopyrimidine et leurs procédés d'utilisation
WO2010075069A1 (fr) 2008-12-16 2010-07-01 Schering Corporation Dérivés de pyranone bicycliques en tant qu'agonistes des récepteurs nicotiniques
EP2305352A1 (fr) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. Inhibiteurs de la 5-alpha-reductase pour le traitement d'hommes aux troubles métaboliques et anthropométriques
WO2011053821A1 (fr) 2009-10-30 2011-05-05 Tranzyme Pharma, Inc. Antagonistes et agonistes inverses macrocycliques du récepteur de la ghréline et leurs méthodes d'utilisation
EP2330124A2 (fr) 2005-08-11 2011-06-08 Amylin Pharmaceuticals Inc. Polypeptides hybrides ayant des propriétés sélectionnables
EP2330125A2 (fr) 2005-08-11 2011-06-08 Amylin Pharmaceuticals, Inc. Polypeptides hybrides ayant des propriétés sélectionnables
WO2011069038A2 (fr) 2009-12-03 2011-06-09 Synergy Pharmaceuticals, Inc. Agonistes de la guanylate cyclase utiles dans le traitement de l'hypercholestérolémie, de l'athérosclérose, d'une coronaropathie, des calculs biliaires, de l'obésité et d'autres maladies cardiovasculaires
WO2011106273A1 (fr) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Nouveaux dérivés benzimidazole cycliques utiles comme agents antidiabétiques
US8101734B2 (en) 2005-04-08 2012-01-24 Noxxon Pharma Ag Ghrelin binding nucleic acids
US8101576B2 (en) 2006-12-13 2012-01-24 Imperial Innovations Limited Compounds and their effects on feeding behaviour
US8217001B2 (en) 2001-09-24 2012-07-10 Imperial Innovations Limited Modification of feeding behavior
US8222217B2 (en) 2007-05-31 2012-07-17 Alize Pharma Sas Unacylated ghrelin as therapeutic agent in the treatment of metabolic disorders
WO2012116145A1 (fr) 2011-02-25 2012-08-30 Merck Sharp & Dohme Corp. Nouveaux dérivés d'azabenzimidazole cyclique utiles en tant qu'agents antidiabétiques
US8318664B2 (en) 2007-05-31 2012-11-27 Alize Pharma Sas Unacylated ghrelin fragments as therapeutic agent in the treatment of obesity
WO2013059222A1 (fr) 2011-10-19 2013-04-25 Merck Sharp & Dohme Corp. Antagonistes des récepteurs de l'orexine à base de 2-pyrydyloxy-4-nitrile
US8440628B2 (en) * 2002-05-21 2013-05-14 Daiichi Sankyo Company, Limited Medical compositions containing ghrelin
US8476408B2 (en) 2008-06-13 2013-07-02 Alize Pharma Sas Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease
WO2013138352A1 (fr) 2012-03-15 2013-09-19 Synergy Pharmaceuticals Inc. Formulations d'agonistes de la guanylate cyclase c et procédés d'utilisation
WO2014022528A1 (fr) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Composés tricycliques antidiabétiques
EP2698157A1 (fr) 2006-09-22 2014-02-19 Merck Sharp & Dohme Corp. Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras
WO2014130608A1 (fr) 2013-02-22 2014-08-28 Merck Sharp & Dohme Corp. Composés bicycliques antidiabétiques
WO2014139388A1 (fr) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques
WO2014151206A1 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonistes de la guanylate cyclase et leurs utilisations
EP2810951A2 (fr) 2008-06-04 2014-12-10 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
WO2014197720A2 (fr) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Agonistes ultra-purs de guanylate cyclase c, leur procédé de production et d'utilisation
US8992928B2 (en) 2006-02-11 2015-03-31 Victor Raso Isolated monoclonal antibody or antigen-binding fragment that cleaves octanoylated native ghrelin
WO2015051725A1 (fr) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Composés tricycliques antidiabétiques
WO2015054500A2 (fr) 2013-10-09 2015-04-16 Synergy Pharmaceuticals, Inc. Agonistes de guanylate cyclase utiles pour la régulation négative de cytokines pro-inflammatoires
WO2016030534A1 (fr) 2014-08-29 2016-03-03 Tes Pharma S.R.L. Inhibiteurs de la semialdéhyde décarboxylase de l'acide alpha-amino-bêta-carboxymuconique
EP2998314A1 (fr) 2007-06-04 2016-03-23 Synergy Pharmaceuticals Inc. Agonistes de guanylase cyclase utiles pour le traitement de troubles gastro-intestinaux, d'inflammation, de cancer et d'autres troubles
US9314764B2 (en) 2000-10-10 2016-04-19 Life Technologies Corporation Apparatus for assay, synthesis and storage, and methods of manufacture, use, and manipulation thereof
US9550821B2 (en) 2011-12-15 2017-01-24 Alize Pharma Sas Modulation of ghrelin levels and ghrelin/unacylated ghrelin ratio using unacylated ghrelin
EP3241839A1 (fr) 2008-07-16 2017-11-08 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres
WO2018069532A1 (fr) 2016-10-14 2018-04-19 Tes Pharma S.R.L. Inhibiteurs de la semialdéhyde décarboxylase de l'acide alpha-amino-bêta-carboxymuconique
WO2018106518A1 (fr) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Composés hétérocycliques antidiabétiques
WO2018118670A1 (fr) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Composés de spirochromane antidiabétiques
US10065189B2 (en) 2004-03-12 2018-09-04 Life Technologies Corporation Nanoliter array loading
US10213761B2 (en) 2004-08-04 2019-02-26 Life Technologies Corporation Coating process for microfluidic sample arrays
US10227644B2 (en) 2000-02-18 2019-03-12 The Board Of Trustees Of The Leland Stanford Junior University Apparatus and methods for parallel processing of microvolume liquid reactions
WO2020104456A1 (fr) 2018-11-20 2020-05-28 Tes Pharma S.R.L Inhibiteurs de la semialdéhyde décarboxylase de l'acide alpha-amino-bêta-carboxymuconique
WO2020167706A1 (fr) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. Agonistes du récepteur de l'orexine 5-alkyl-pyrrolidine
WO2021026047A1 (fr) 2019-08-08 2021-02-11 Merck Sharp & Dohme Corp. Agonistes du récepteur de l'orexine de type pyrrolidine et pipéridine hétéroaryle
WO2022040070A1 (fr) 2020-08-18 2022-02-24 Merck Sharp & Dohme Corp. Agonistes du récepteur de l'orexine de type bicycloheptane pyrrolidine
US12070731B2 (en) 2004-08-04 2024-08-27 Life Technologies Corporation Methods and systems for aligning dispensing arrays with microfluidic sample arrays

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003302264A1 (en) 2002-12-20 2004-09-09 Biotrove, Inc. Assay apparatus and method using microfluidic arrays

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997021730A1 (fr) * 1995-12-13 1997-06-19 Merck & Co., Inc. Famille de recepteurs secretagogues d'hormones de croissance
WO2000002919A1 (fr) * 1998-07-13 2000-01-20 Merck & Co., Inc. Recepteurs et acides nucleiques en rapport avec un secretagogue d'hormone de croissance
WO2000009538A2 (fr) * 1998-08-10 2000-02-24 Merck & Co., Inc. Recepteur de secretagogue d'hormone de croissance canine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997021730A1 (fr) * 1995-12-13 1997-06-19 Merck & Co., Inc. Famille de recepteurs secretagogues d'hormones de croissance
WO2000002919A1 (fr) * 1998-07-13 2000-01-20 Merck & Co., Inc. Recepteurs et acides nucleiques en rapport avec un secretagogue d'hormone de croissance
WO2000009538A2 (fr) * 1998-08-10 2000-02-24 Merck & Co., Inc. Recepteur de secretagogue d'hormone de croissance canine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KOJIMA MASAYASU ET AL: "Ghrelin is a growth-hormone-releasing acylated peptide from stomach." NATURE (LONDON), vol. 402, no. 6762, 9 December 1999 (1999-12-09), pages 656-660, XP002187791 ISSN: 0028-0836 cited in the application *
SMITH R G ET AL: "A nonpeptidyl growth hormone secretagogue." SCIENCE, (1993 JUN 11) 260 (5114) 1640-3. , XP002187790 cited in the application *

Cited By (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10227644B2 (en) 2000-02-18 2019-03-12 The Board Of Trustees Of The Leland Stanford Junior University Apparatus and methods for parallel processing of microvolume liquid reactions
US10378049B2 (en) 2000-02-18 2019-08-13 The Board Of Trustees Of The Leland Stanford Junior University Apparatus and methods for parallel processing of microvolume liquid reactions
US9968903B2 (en) 2000-10-10 2018-05-15 Life Technologies Corporation Apparatus for assay, synthesis and storage, and methods of manufacture, use, and manipulation thereof
US9314764B2 (en) 2000-10-10 2016-04-19 Life Technologies Corporation Apparatus for assay, synthesis and storage, and methods of manufacture, use, and manipulation thereof
US6716629B2 (en) 2000-10-10 2004-04-06 Biotrove, Inc. Apparatus for assay, synthesis and storage, and methods of manufacture, use, and manipulation thereof
WO2002060472A1 (fr) * 2001-01-31 2002-08-08 Chugai Seiyaku Kabushiki Kaisha Remedes pour des etats d'hyponutrition
WO2002090387A1 (fr) * 2001-05-10 2002-11-14 Queensland University Of Technology Diagnostic et therapie des cancers du systeme reproducteur
US8217001B2 (en) 2001-09-24 2012-07-10 Imperial Innovations Limited Modification of feeding behavior
US7666833B2 (en) 2001-12-18 2010-02-23 Alizé Pharma SAS Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
US8071368B2 (en) 2001-12-18 2011-12-06 Alizé Pharma SAS Methods for promoting growth and survival of insulin-secreting cells
WO2003051389A3 (fr) * 2001-12-18 2003-09-12 Theratechnologies Inc Compositions pharmaceutiques comprenant de la ghreline non acylee et utilisations therapeutiques de ces compositions
US7485620B2 (en) 2001-12-18 2009-02-03 Alizé Pharma SAS Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
US8518893B2 (en) 2002-05-21 2013-08-27 Asubio Pharma Co. Ltd. Medical compositions containing ghrelin
US8440628B2 (en) * 2002-05-21 2013-05-14 Daiichi Sankyo Company, Limited Medical compositions containing ghrelin
WO2004002986A2 (fr) 2002-06-28 2004-01-08 Banyu Pharmaceutical Co., Ltd. Nouveaux dérivés de benzimidazole
WO2004004772A1 (fr) * 2002-07-05 2004-01-15 Chugai Seiyaku Kabushiki Kaisha Traitement antidiabetique
WO2004013274A2 (fr) 2002-08-01 2004-02-12 Noxxon Pharma Ag Acides nucleiques a liaison de ghreline
WO2004013274A3 (fr) * 2002-08-01 2004-05-13 Noxxon Pharma Ag Acides nucleiques a liaison de ghreline
US7750140B2 (en) 2002-08-01 2010-07-06 Noxxon Pharma Ag Ghrelin binding nucleic acids
JP2006501864A (ja) * 2002-08-01 2006-01-19 ノクソン・フアルマ・アクチエンゲゼルシヤフト グレリン結合核酸
EP1546389A2 (fr) * 2002-09-06 2005-06-29 Elixir Pharmaceuticals, Inc. Regulation de l'axe hormone de croissance/igf-1
EP1546389A4 (fr) * 2002-09-06 2006-07-26 Elixir Pharmaceuticals Inc Regulation de l'axe hormone de croissance/igf-1
WO2004024183A1 (fr) * 2002-09-12 2004-03-25 Pharmexa A/S Immunisation contre la ghreline autologue
WO2004056869A1 (fr) * 2002-12-20 2004-07-08 7Tm Pharma A/S Agoniste inverse du recepteur de la ghreline pour reguler des comportements alimentaires
WO2004084943A1 (fr) * 2003-03-19 2004-10-07 Beth Israel Deaconess Medical Center, Inc Utilisation d'antagonistes de la ghrelin ou du recepteur de la ghrelin pour traiter l'inflammation intestinale
WO2005000343A1 (fr) * 2003-06-11 2005-01-06 Allergan, Inc. Utilisation d'une toxine clostridiale pour reduire l'appetit
WO2005026211A3 (fr) * 2003-09-05 2005-06-16 Lilly Co Eli Anticorps anti-ghreline
WO2005026211A2 (fr) * 2003-09-05 2005-03-24 Eli Lilly And Company Anticorps anti-ghreline
EP1694355A4 (fr) * 2003-10-24 2009-07-29 Alize Pharma Sas Utilisation de compositions de ghreline et de ghreline non acylee dans des etats pathologiques lies a l'insuline
US7825090B2 (en) 2003-10-24 2010-11-02 Alizé Pharma SAS Use of ghrelin and unacylated ghrelin compositions for treating insulin resistance
EP1694355A1 (fr) * 2003-10-24 2006-08-30 THE ACADEMIC HOSPITAL ROTTERDAM acting under the name Erasmus MC Utilisation de compositions de ghreline et de ghreline non acylee dans des etats pathologiques lies a l'insuline
US7252665B2 (en) 2003-10-31 2007-08-07 Medtronic, Inc Ablation of stomach lining to reduce stomach acid secretion
US7282050B2 (en) 2003-10-31 2007-10-16 Medtronic, Inc. Ablation of exterior of stomach to treat obesity
JP2007513608A (ja) * 2003-11-10 2007-05-31 ノクソン・フアルマ・アクチエンゲゼルシヤフト 生物活性グレリンに特異的に結合する核酸
JP4823067B2 (ja) * 2003-11-10 2011-11-24 ノクソン・フアルマ・アクチエンゲゼルシヤフト 生物活性グレリンに特異的に結合する核酸
EP2088154A1 (fr) 2004-03-09 2009-08-12 Ironwood Pharmaceuticals, Inc. Procédés et compositions pour le traitement de troubles gastro-intestinaux
US10065189B2 (en) 2004-03-12 2018-09-04 Life Technologies Corporation Nanoliter array loading
US10974247B2 (en) 2004-03-12 2021-04-13 Life Technologies Corporation Nanoliter array loading
EP2305352A1 (fr) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. Inhibiteurs de la 5-alpha-reductase pour le traitement d'hommes aux troubles métaboliques et anthropométriques
WO2005097830A3 (fr) * 2004-04-07 2005-12-22 Aditech Pharma Ab Utilisations d'elements de liaison isoles capables de reduire l'activite biologique de composes secretagogues
WO2005097830A2 (fr) * 2004-04-07 2005-10-20 Aditech Pharma Ab Utilisations d'elements de liaison isoles capables de reduire l'activite biologique de composes secretagogues
WO2005097831A2 (fr) * 2004-04-07 2005-10-20 Gastrotech Pharma A/S Utilisations d'elements de liaison isoles capables de se lier specifiquement a des secretagogues
WO2005097831A3 (fr) * 2004-04-07 2005-12-22 Gastrotech Pharma As Utilisations d'elements de liaison isoles capables de se lier specifiquement a des secretagogues
WO2005114180A2 (fr) * 2004-05-14 2005-12-01 Novo Nordisk A/S Antagonistes fonctionnels du ghs-r
WO2005112903A3 (fr) * 2004-05-14 2006-02-02 Novo Nordisk As Utilisation d'antagonistes de la ghrelin pour le traitement de certaines maladies du systeme nerveux central
WO2005112903A2 (fr) * 2004-05-14 2005-12-01 Novo Nordisk A/S Utilisation d'antagonistes de la ghrelin pour le traitement de certaines maladies du systeme nerveux central
WO2005114180A3 (fr) * 2004-05-14 2006-04-13 Novo Nordisk As Antagonistes fonctionnels du ghs-r
WO2005113600A2 (fr) * 2004-05-18 2005-12-01 Haptogen Ltd Methodes de regulation, de traitement et de prise en charge de l'obesite
WO2005113600A3 (fr) * 2004-05-18 2006-06-08 Haptogen Ltd Methodes de regulation, de traitement et de prise en charge de l'obesite
WO2006019577A1 (fr) * 2004-07-14 2006-02-23 Eli Lilly And Company Anticorps anti-ghreline
US10213761B2 (en) 2004-08-04 2019-02-26 Life Technologies Corporation Coating process for microfluidic sample arrays
US12070731B2 (en) 2004-08-04 2024-08-27 Life Technologies Corporation Methods and systems for aligning dispensing arrays with microfluidic sample arrays
US11154834B2 (en) 2004-08-04 2021-10-26 Life Technologies Corporation Coating process for microfluidic sample arrays
EP2286840A2 (fr) 2004-11-01 2011-02-23 Amylin Pharmaceuticals, Inc. Traitement de l'obésité et de maladies liés à l'obésité
EP2286839A2 (fr) 2004-11-01 2011-02-23 Amylin Pharmaceuticals, Inc. Traitement de l'obésité et de maladies liés à l'obésité
EP2286837A2 (fr) 2004-11-01 2011-02-23 Amylin Pharmaceuticals, Inc. Traitement de l'obésité et de maladies liés à l'obésité
EP2286838A2 (fr) 2004-11-01 2011-02-23 Amylin Pharmaceuticals, Inc. Traitement de l'obésité et de maladies liés à l'obésité
EP2127676A2 (fr) 2004-11-01 2009-12-02 Amylin Pharmaceuticals, Inc. Traitement de l'obésité et les maladies et troubles liés à l'obésité
WO2006091381A1 (fr) * 2005-02-23 2006-08-31 Eli Lilly And Company Anticorps anti-ghreline humanises
US7479271B2 (en) 2005-02-23 2009-01-20 Eli Lilly And Company Humanized anti-ghrelin antibodies
US8101734B2 (en) 2005-04-08 2012-01-24 Noxxon Pharma Ag Ghrelin binding nucleic acids
US7736392B2 (en) 2005-04-28 2010-06-15 Medtronic, Inc. Bulking of upper esophageal sphincter for treatment of obesity
EP2330124A2 (fr) 2005-08-11 2011-06-08 Amylin Pharmaceuticals Inc. Polypeptides hybrides ayant des propriétés sélectionnables
EP2330125A2 (fr) 2005-08-11 2011-06-08 Amylin Pharmaceuticals, Inc. Polypeptides hybrides ayant des propriétés sélectionnables
WO2007041052A2 (fr) 2005-09-29 2007-04-12 Merck & Co., Inc. Derives spiropiperidines acyles convenant comme modulateurs des recepteurs de la melanocortine-4
US8992928B2 (en) 2006-02-11 2015-03-31 Victor Raso Isolated monoclonal antibody or antigen-binding fragment that cleaves octanoylated native ghrelin
WO2007095347A2 (fr) * 2006-02-13 2007-08-23 The Gov. Of The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Procedes et compositions associes aux antagonistes du ghs-r
WO2007095347A3 (fr) * 2006-02-13 2007-12-21 Us Gov Health & Human Serv Procedes et compositions associes aux antagonistes du ghs-r
EP2946778A1 (fr) 2006-09-22 2015-11-25 Merck Sharp & Dohme Corp. Procédé de traitement utilisant des inhibiteurs de la synthèse d'acides gras
EP2698157A1 (fr) 2006-09-22 2014-02-19 Merck Sharp & Dohme Corp. Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras
WO2008060476A2 (fr) 2006-11-15 2008-05-22 Schering Corporation Composés hétérocycliques contenant de l'azote et leurs procédés d'utilisation
US8101576B2 (en) 2006-12-13 2012-01-24 Imperial Innovations Limited Compounds and their effects on feeding behaviour
US8222217B2 (en) 2007-05-31 2012-07-17 Alize Pharma Sas Unacylated ghrelin as therapeutic agent in the treatment of metabolic disorders
US8318664B2 (en) 2007-05-31 2012-11-27 Alize Pharma Sas Unacylated ghrelin fragments as therapeutic agent in the treatment of obesity
EP2998314A1 (fr) 2007-06-04 2016-03-23 Synergy Pharmaceuticals Inc. Agonistes de guanylase cyclase utiles pour le traitement de troubles gastro-intestinaux, d'inflammation, de cancer et d'autres troubles
WO2009110510A1 (fr) 2008-03-06 2009-09-11 萬有製薬株式会社 Dérivé d'alkylaminopyridine
EP2810951A2 (fr) 2008-06-04 2014-12-10 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
US8476408B2 (en) 2008-06-13 2013-07-02 Alize Pharma Sas Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease
EP3241839A1 (fr) 2008-07-16 2017-11-08 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres
WO2010047982A1 (fr) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Nouveaux dérivés de benzimidazole cycliques utiles comme agents anti-diabétiques
WO2010051236A1 (fr) 2008-10-30 2010-05-06 Merck Sharp & Dohme Corp. Antagonistes d'isonicotinamide des récepteurs de l'orexine
WO2010051206A1 (fr) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Nouveaux agents antidiabétiques utiles avec des dérivés de benzimidazole cycliques
WO2010075068A1 (fr) 2008-12-16 2010-07-01 Schering Corporation Dérivés de pyridopyrimidine et leurs procédés d'utilisation
WO2010075069A1 (fr) 2008-12-16 2010-07-01 Schering Corporation Dérivés de pyranone bicycliques en tant qu'agonistes des récepteurs nicotiniques
WO2011053821A1 (fr) 2009-10-30 2011-05-05 Tranzyme Pharma, Inc. Antagonistes et agonistes inverses macrocycliques du récepteur de la ghréline et leurs méthodes d'utilisation
WO2011069038A2 (fr) 2009-12-03 2011-06-09 Synergy Pharmaceuticals, Inc. Agonistes de la guanylate cyclase utiles dans le traitement de l'hypercholestérolémie, de l'athérosclérose, d'une coronaropathie, des calculs biliaires, de l'obésité et d'autres maladies cardiovasculaires
WO2011106273A1 (fr) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Nouveaux dérivés benzimidazole cycliques utiles comme agents antidiabétiques
WO2012116145A1 (fr) 2011-02-25 2012-08-30 Merck Sharp & Dohme Corp. Nouveaux dérivés d'azabenzimidazole cyclique utiles en tant qu'agents antidiabétiques
EP3243385A1 (fr) 2011-02-25 2017-11-15 Merck Sharp & Dohme Corp. Nouveaux dérivés d'azabenzimidazole cyclique utiles en tant qu'agents antidiabétiques
WO2013059222A1 (fr) 2011-10-19 2013-04-25 Merck Sharp & Dohme Corp. Antagonistes des récepteurs de l'orexine à base de 2-pyrydyloxy-4-nitrile
US9550821B2 (en) 2011-12-15 2017-01-24 Alize Pharma Sas Modulation of ghrelin levels and ghrelin/unacylated ghrelin ratio using unacylated ghrelin
EP4309673A2 (fr) 2012-03-15 2024-01-24 Bausch Health Ireland Limited Formulations d'agonistes de guanylate cyclase c et leurs procédés d'utilisation
EP3708179A1 (fr) 2012-03-15 2020-09-16 Bausch Health Ireland Limited Formulations d'agonistes de guanylate cyclase c et leurs procédés d'utilisation
WO2013138352A1 (fr) 2012-03-15 2013-09-19 Synergy Pharmaceuticals Inc. Formulations d'agonistes de la guanylate cyclase c et procédés d'utilisation
WO2014022528A1 (fr) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Composés tricycliques antidiabétiques
WO2014130608A1 (fr) 2013-02-22 2014-08-28 Merck Sharp & Dohme Corp. Composés bicycliques antidiabétiques
WO2014139388A1 (fr) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques
WO2014151206A1 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonistes de la guanylate cyclase et leurs utilisations
WO2014197720A2 (fr) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Agonistes ultra-purs de guanylate cyclase c, leur procédé de production et d'utilisation
EP4424697A2 (fr) 2013-06-05 2024-09-04 Bausch Health Ireland Limited Agonistes ultra-purs de guanylate cyclase c, leur procédé de fabrication et d'utilisation
WO2015051725A1 (fr) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Composés tricycliques antidiabétiques
WO2015054500A2 (fr) 2013-10-09 2015-04-16 Synergy Pharmaceuticals, Inc. Agonistes de guanylate cyclase utiles pour la régulation négative de cytokines pro-inflammatoires
US10513499B2 (en) 2014-08-29 2019-12-24 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
US9708272B2 (en) 2014-08-29 2017-07-18 Tes Pharma S.R.L. Inhibitors of α-amino-β-carboxymuconic acid semialdehyde decarboxylase
WO2016030534A1 (fr) 2014-08-29 2016-03-03 Tes Pharma S.R.L. Inhibiteurs de la semialdéhyde décarboxylase de l'acide alpha-amino-bêta-carboxymuconique
US11254644B2 (en) 2014-08-29 2022-02-22 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
WO2018069532A1 (fr) 2016-10-14 2018-04-19 Tes Pharma S.R.L. Inhibiteurs de la semialdéhyde décarboxylase de l'acide alpha-amino-bêta-carboxymuconique
WO2018106518A1 (fr) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Composés hétérocycliques antidiabétiques
WO2018118670A1 (fr) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Composés de spirochromane antidiabétiques
WO2020104456A1 (fr) 2018-11-20 2020-05-28 Tes Pharma S.R.L Inhibiteurs de la semialdéhyde décarboxylase de l'acide alpha-amino-bêta-carboxymuconique
WO2020167706A1 (fr) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. Agonistes du récepteur de l'orexine 5-alkyl-pyrrolidine
WO2021026047A1 (fr) 2019-08-08 2021-02-11 Merck Sharp & Dohme Corp. Agonistes du récepteur de l'orexine de type pyrrolidine et pipéridine hétéroaryle
WO2022040070A1 (fr) 2020-08-18 2022-02-24 Merck Sharp & Dohme Corp. Agonistes du récepteur de l'orexine de type bicycloheptane pyrrolidine

Also Published As

Publication number Publication date
AU2001259056A1 (en) 2001-11-26
WO2001087335A3 (fr) 2002-05-16
EP1286697A2 (fr) 2003-03-05

Similar Documents

Publication Publication Date Title
US20050201938A1 (en) Method for selectively inhibiting ghrelin action
WO2001087335A2 (fr) Procede d'inhibition selective de la ghreline
Castaneda et al. Ghrelin in the regulation of body weight and metabolism
RU2351359C2 (ru) Применение оксинтомодулина, способ и фармацевтическая композиция для профилактики или лечения избыточной массы тела
JP6312748B2 (ja) 脂質動員特性を有する糖タンパク質およびその治療的使用
JP2021185178A (ja) 胆汁酸に関係した障害の治療方法
HU228621B1 (en) Modification of feeding behavior
KR20150104579A (ko) 담즙산 항상성의 조절 및 담즙산 질환 및 질병의 치료 방법
CN103732618A (zh) 新型泌酸调节肽衍生物和包含该泌酸调节肽衍生物的用于治疗肥胖的药物组合物
BR112013033175A2 (pt) sequência de peptídeo, subsequência, composição, composição farmacêutica, molécula de ácido nucleico, vetor, célula transformada ou hospedeira, método de tratamento de um indivíduo, método para melhorar o metabolismo da glicose em um indivíduo e método para identificar uma sequência peptédica
JP2008518941A (ja) 大腸連続性を伴う短腸症候群患者の治療
JP7165495B2 (ja) 運動調節機能向上剤
CN110099694A (zh) 低体温改善剂
AU2016242935A1 (en) Methods for treating obesity and nonalcoholic fatty liver disease or nonalcoholic steatohepatitis using glucagon receptor antagonistic antibodies
US20220340668A1 (en) Treatment of liver disease or disorder comprising actrii receptor antagonists
US20060269550A1 (en) Anti-ghrelin fab antibodies
JP2011506371A (ja) 抗Ｆａｓリガンド抗体を含有する天疱瘡の治療薬
CN118055767A (zh) 新颖的组合施用
JP5875190B2 (ja) メチルグリオキサール−スカベンジング化合物ならびに疼痛および／または痛覚過敏の予防および治療のためのその使用
US10005838B2 (en) Milk fat globule epidermal growth factor 8 regulates fatty acid uptake
JP2007523196A (ja) Ｎｔ−４／５を用いて肥満または糖尿病を処置する方法
CN111905096A (zh) 用于维持最佳体重和血糖的新的多肽激素的鉴定
CN110177567A (zh) 含有hGH融合蛋白的治疗生长激素缺乏症的药物组合物
EP3892289A1 (fr) Composition pharmaceutique, comprenant un peptide inhibiteur contre la signalisation fas, destinée à la prévention ou au traitement de l'obésité, du foie gras, ou de la stéatohépatite
CA3180559A1 (fr) Administration d'antagoniste de cebp-beta et methodes d'utilisation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 10258259

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2001932539

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001932539

Country of ref document: EP

NENP Non-entry into the national phase in:

Ref country code: JP